Kalshi launches prediction markets for clinical trials and FDA drug approvals

Jul 16, 2026

Prediction market Kalshi launched trading on clinical trial outcomes and FDA drug approvals on July 16, 2026, in partnership with AI firm AppliedXL. The platform allows investors to bet on specific late-stage trial results for drugs from companies like Gilead and Sanofi, isolating these events from stock performance. To prevent insider trading, the platform requires employment verification and bans traders with nonpublic information.

Kalshi prediction market launch

▪The platform allows investors to bet on a single drug's approval, isolating the event from the company's overall stock performance.
▪At launch, Kalshi offered 13 new biotech contracts.
▪Kalshi launched the new biotech markets in partnership with AppliedXL, an AI-powered firm that monitors and predicts clinical trial outcomes.
▪On July 16, 2026, prediction market platform Kalshi began offering wagers on the outcomes of clinical trials and FDA regulatory decisions.

Clinical trial betting mechanics

▪Each contract is based on a public document, such as the registered primary endpoint on ClinicalTrials.gov or an FDA approval letter.
▪AppliedXL defines the criteria for interpreting the outcome document before the contract opens for trading.
▪The pilot program is limited to bets on the outcomes of late-stage clinical trials.
▪A contract for a specific trial will only be listed after the trial has finished enrolling participants.

Available drug contracts

▪Available contracts include bets on FDA approval for Gilead's experimental cancer drug, anito-cel, and medicines from Sanofi.
▪Other available bets include a contract for Summit Therapeutics' experimental lung cancer drug, ivonescimab.
▪A contract is available on whether an early Alzheimer's drug from AriBio will meet the main goals of its late-stage trial.

Trader eligibility restrictions

▪Trading is prohibited for anyone who possesses material nonpublic information about the trials or regulatory decisions.
▪The platform requires employment verification for all traders participating in the biotech markets.